Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 005
mi
from
Wilkes-Barre, PA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 005
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 080
mi
from
Wynnewood, PA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 080
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 294
mi
from
Yardley, PA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 294
mi
from
Yardley, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 046
mi
from
York, PA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 046
mi
from
York, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 084
mi
from
Providence, RI
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 084
mi
from
Providence, RI
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 027
mi
from
Charleston, SC
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 027
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 033
mi
from
Columbia, SC
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 033
mi
from
Columbia, SC
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative site 066
mi
from
Charleston, SC
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative site 066
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 243
mi
from
Greenville, SC
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 243
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 014
mi
from
Rapid City, SD
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 014
mi
from
Rapid City, SD
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 094
mi
from
Sioux Falls, SD
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 094
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 040
mi
from
Austin, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 040
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative site 006
mi
from
Houston, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative site 006
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 028
mi
from
Dallas, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 028
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 2012
mi
from
Fort Worth, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 2012
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site #007
mi
from
Dallas, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site #007
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 076
mi
from
Houston, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 076
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 074
mi
from
Austin, TX
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 074
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 016
mi
from
Chesapeake, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 016
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 004
mi
from
Falls Church, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 004
mi
from
Falls Church, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 117
mi
from
Lynchburg, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 117
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 065
mi
from
Newport News, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 065
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative site 041
mi
from
Norfolk, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative site 041
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 072
mi
from
Richmond, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 072
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 023
mi
from
Roanoke, VA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 023
mi
from
Roanoke, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 069
mi
from
Spokane, WA
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 069
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 071
mi
from
Green Bay, WI
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 071
mi
from
Green Bay, WI
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 042
mi
from
Madison, WI
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 042
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated:  3/24/2013
Forest Investigative Site 049
mi
from
Milwaukee, WI
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Status: Enrolling
Updated: 3/24/2013
Forest Investigative Site 049
mi
from
Milwaukee, WI
Click here to add this to my saved trials
3D Ultrasound in Women With Vacuum or Forceps Deliveries
3-Dimension Ultrasound Findings in Women Who Have Undergone Vacuum Versus Forceps-Assisted Vaginal Deliveries
Status: Enrolling
Updated:  3/29/2013
University of Rochester
mi
from
Rochester, NY
3D Ultrasound in Women With Vacuum or Forceps Deliveries
3-Dimension Ultrasound Findings in Women Who Have Undergone Vacuum Versus Forceps-Assisted Vaginal Deliveries
Status: Enrolling
Updated: 3/29/2013
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Acute Neurological ICU Sedation Trial (ANIST)
Acute Neurological ICU Sedation Trial (ANIST)
Status: Enrolling
Updated:  4/11/2013
Johns Hopkins University
mi
from
Baltimore, MD
Acute Neurological ICU Sedation Trial (ANIST)
Acute Neurological ICU Sedation Trial (ANIST)
Status: Enrolling
Updated: 4/11/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of Rozerem on Sleep Among People With Traumatic Brain Injury
Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury
Status: Enrolling
Updated:  4/15/2013
Kessler Foundation Research Center
mi
from
West Orange, NJ
Effect of Rozerem on Sleep Among People With Traumatic Brain Injury
Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury
Status: Enrolling
Updated: 4/15/2013
Kessler Foundation Research Center
mi
from
West Orange, NJ
Click here to add this to my saved trials
Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury
CURE-SCI. Clinical Utilization of CNS Growth Factor Release in Response to Electrical Stimulation Following Spinal Cord Injury.
Status: Enrolling
Updated:  4/15/2013
Kennedy Krieger Institute
mi
from
Baltimore, MD
Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury
CURE-SCI. Clinical Utilization of CNS Growth Factor Release in Response to Electrical Stimulation Following Spinal Cord Injury.
Status: Enrolling
Updated: 4/15/2013
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated:  4/24/2013
University of California - Los Angeles
mi
from
Los Angeles, CA
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated: 4/24/2013
University of California - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated:  4/24/2013
University of Miami
mi
from
Miami, FL
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated: 4/24/2013
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated:  4/24/2013
LifeLink Health Care Institute
mi
from
Tampa, FL
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated: 4/24/2013
LifeLink Health Care Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated:  4/24/2013
Emory University Hospital
mi
from
Atlanta, GA
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated: 4/24/2013
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated:  4/24/2013
Indiana University
mi
from
Indianapolis, IN
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Status: Enrolling
Updated: 4/24/2013
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects
Status: Enrolling
Updated:  4/30/2013
Miami Research Associates
mi
from
South Miami, FL
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects
Status: Enrolling
Updated: 4/30/2013
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients
A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients
Status: Enrolling
Updated:  4/30/2013
Center for Dental Research Loma Linda University School
mi
from
Loma Linda, CA
Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients
A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients
Status: Enrolling
Updated: 4/30/2013
Center for Dental Research Loma Linda University School
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients
A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients
Status: Enrolling
Updated:  4/30/2013
Big Grins
mi
from
Fort Collins, CO
Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients
A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients
Status: Enrolling
Updated: 4/30/2013
Big Grins
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy
Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy
Status: Enrolling
Updated:  5/1/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy
Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy
Status: Enrolling
Updated: 5/1/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Lung Transplant Specimen Repository and Data Registry Protocol
Lung Transplant Specimen Repository and Data Registry Protocol
Status: Enrolling
Updated:  5/2/2013
Ohio State University
mi
from
Columbus, OH
Lung Transplant Specimen Repository and Data Registry Protocol
Lung Transplant Specimen Repository and Data Registry Protocol
Status: Enrolling
Updated: 5/2/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
University of San Francisco-Fresno Medical Center
mi
from
Fresno, CA
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
University of San Francisco-Fresno Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
University of California, Davis Medical Center
mi
from
Sacramento, CA
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
UCSF-Moffitt Hospital
mi
from
San Francisco, CA
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
UCSF-Moffitt Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
University of California, San Francisco (UCSF)-Moffitt Hospital
mi
from
San Francisco, CA
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
University of California, San Francisco (UCSF)-Moffitt Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
Centura St. Anthony Central Hospital
mi
from
Denver, CO
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
Centura St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
Denver Health Medical Center
mi
from
Denver, CO
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated:  5/3/2013
Rose Medical Center
mi
from
Denver, CO
Statins for Acutely Injured Lungs From Sepsis
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Status: Enrolling
Updated: 5/3/2013
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials